These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
374 related articles for article (PubMed ID: 36526110)
1. Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines. Oladejo M; Paulishak W; Wood L Semin Cancer Biol; 2023 Jan; 88():81-95. PubMed ID: 36526110 [TBL] [Abstract][Full Text] [Related]
2. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034 [TBL] [Abstract][Full Text] [Related]
3. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment. Song Y; Fu Y; Xie Q; Zhu B; Wang J; Zhang B Front Immunol; 2020; 11():1956. PubMed ID: 32983126 [TBL] [Abstract][Full Text] [Related]
4. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Xing R; Gao J; Cui Q; Wang Q Front Immunol; 2021; 12():783236. PubMed ID: 34899747 [TBL] [Abstract][Full Text] [Related]
5. Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway. Zheng X; Luo Y; Xiong Y; Liu X; Zeng C; Lu X; Wang X; Cheng Y; Wang S; Lan H; Wang K; Weng Z; Bi W; Gan X; Jia X; Wang L; Wang Y J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056895 [TBL] [Abstract][Full Text] [Related]
6. Resistance to immune checkpoint inhibitors and the tumor microenvironment. Kawashima S; Togashi Y Exp Dermatol; 2023 Mar; 32(3):240-249. PubMed ID: 36437644 [TBL] [Abstract][Full Text] [Related]
8. An overview of up-and-coming immune checkpoint inhibitors for pancreatic cancer. Mahadevia H; Uson Junior PLS; Wang J; Borad M; Babiker H Expert Opin Pharmacother; 2024; 25(1):79-90. PubMed ID: 38193476 [TBL] [Abstract][Full Text] [Related]
9. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy. Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476 [TBL] [Abstract][Full Text] [Related]
10. Enhancing Dendritic Cell Cancer Vaccination: The Synergy of Immune Checkpoint Inhibitors in Combined Therapies. Zanotta S; Galati D; De Filippi R; Pinto A Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39062753 [TBL] [Abstract][Full Text] [Related]
11. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance. Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690 [TBL] [Abstract][Full Text] [Related]
12. Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors. Yan T; Yu L; Shangguan D; Li W; Liu N; Chen Y; Fu Y; Tang J; Liao D Int Immunopharmacol; 2023 Feb; 115():109638. PubMed ID: 36587500 [TBL] [Abstract][Full Text] [Related]
13. Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks. Meng L; Wu H; Wu J; Ding P; He J; Sang M; Liu L Cell Death Dis; 2024 Jan; 15(1):3. PubMed ID: 38177102 [TBL] [Abstract][Full Text] [Related]
14. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome. Araujo B de Lima V; Borch A; Hansen M; Draghi A; Spanggaard I; Rohrberg K; Reker Hadrup S; Lassen U; Svane IM Cytotherapy; 2020 Apr; 22(4):204-213. PubMed ID: 32201034 [TBL] [Abstract][Full Text] [Related]
15. Immune checkpoints in the tumor microenvironment. Toor SM; Sasidharan Nair V; Decock J; Elkord E Semin Cancer Biol; 2020 Oct; 65():1-12. PubMed ID: 31265893 [TBL] [Abstract][Full Text] [Related]
16. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner. Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370 [TBL] [Abstract][Full Text] [Related]
17. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Zhang Y; Zhang Z Cell Mol Immunol; 2020 Aug; 17(8):807-821. PubMed ID: 32612154 [TBL] [Abstract][Full Text] [Related]
18. Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy. Su L; Hao Y; Li R; Pan W; Ma X; Weng J; Min Y Acta Biomater; 2022 Dec; 154():401-411. PubMed ID: 36241013 [TBL] [Abstract][Full Text] [Related]
19. Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression. Saleh R; Elkord E Semin Cancer Biol; 2020 Oct; 65():13-27. PubMed ID: 31362073 [TBL] [Abstract][Full Text] [Related]
20. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma. Diggs LP; Ruf B; Ma C; Heinrich B; Cui L; Zhang Q; McVey JC; Wabitsch S; Heinrich S; Rosato U; Lai W; Subramanyam V; Longerich T; Loosen SH; Luedde T; Neumann UP; Desar S; Kleiner D; Gores G; Wang XW; Greten TF J Hepatol; 2021 May; 74(5):1145-1154. PubMed ID: 33276030 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]